- Home
- MGNX vs AMRN Comparison
MGNX vs AMRN Comparison
Compare MGNX & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- AMRN
- Stock Information
- Founded
- MGNX 2000
- AMRN 1989
- Country
- MGNX United States
- AMRN Ireland
- Employees
- MGNX N/A
- AMRN N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- AMRN Health Care
- Exchange
- MGNX Nasdaq
- AMRN Nasdaq
- Market Cap
- MGNX 202.7M
- AMRN 189.2M
- IPO Year
- MGNX 2013
- AMRN 1993
- Fundamental
- Price
- MGNX $2.86
- AMRN $0.55
- Analyst Decision
- MGNX Hold
- AMRN Buy
- Analyst Count
- MGNX 10
- AMRN 1
- Target Price
- MGNX $7.17
- AMRN N/A
- AVG Volume (30 Days)
- MGNX 642.4K
- AMRN 1.1M
- Earning Date
- MGNX 03-06-2025
- AMRN 02-27-2025
- Dividend Yield
- MGNX N/A
- AMRN N/A
- EPS Growth
- MGNX N/A
- AMRN N/A
- EPS
- MGNX N/A
- AMRN N/A
- Revenue
- MGNX $141,329,000.00
- AMRN $241,021,000.00
- Revenue This Year
- MGNX $174.73
- AMRN N/A
- Revenue Next Year
- MGNX N/A
- AMRN N/A
- P/E Ratio
- MGNX N/A
- AMRN N/A
- Revenue Growth
- MGNX 16.68
- AMRN N/A
- 52 Week Low
- MGNX $2.79
- AMRN $0.43
- 52 Week High
- MGNX $21.88
- AMRN $1.36
- Technical
- Relative Strength Index (RSI)
- MGNX 34.55
- AMRN 50.48
- Support Level
- MGNX $2.93
- AMRN $0.55
- Resistance Level
- MGNX $3.16
- AMRN $0.61
- Average True Range (ATR)
- MGNX 0.18
- AMRN 0.04
- MACD
- MGNX -0.02
- AMRN -0.00
- Stochastic Oscillator
- MGNX 1.90
- AMRN 26.56
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.